Streetbeat News

Analyst Ratings

FIBK

First Interstate BancSys (NASDAQ:FIBK) has received mixed analyst ratings over the past three months, with a recent positive shift in average price targets. Analysts have raised their price targets, reflecting a more optimistic outlook despite the company's recent revenue decline and financial challenges.

Portfolio Pulse from Benzinga Insights

September 27, 2024 | 3:00 pm

KNSL

Kinsale Capital Group (NYSE:KNSL) has received mixed analyst ratings, with a recent trend towards bullish sentiment. Analysts have raised price targets, reflecting optimism about the company's future performance. Kinsale's financial metrics, including revenue growth and profitability, surpass industry averages, indicating strong financial health.

Portfolio Pulse from Benzinga Insights

September 27, 2024 | 3:00 pm

V

Macquarie analyst Paul Golding maintains an Outperform rating on Visa with a $300 price target, indicating confidence in Visa's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 2:55 pm

JSPR

JMP Securities analyst Silvan Tuerkcan has reiterated a Market Outperform rating for Jasper Therapeutics (NASDAQ:JSPR) and maintained a $70 price target.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 2:55 pm

SNX

Barrington Research has reiterated its 'Outperform' rating for TD Synnex (NYSE:SNX) with a maintained price target of $138.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 2:53 pm

ENTA

JMP Securities analyst Roy Buchanan has reiterated a Market Outperform rating for Enanta Pharma (NASDAQ:ENTA) and maintained a price target of $22.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 2:51 pm

SYM

BWS Financial analyst Hamed Khorsand maintains a Sell rating on Symbotic (NASDAQ:SYM) with a $10 price target.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 2:51 pm

ARLO

BWS Financial analyst Hamed Khorsand has reiterated a Buy rating for Arlo Technologies, maintaining a price target of $24.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 2:48 pm

CRNX

JMP Securities has reiterated its Market Outperform rating for Crinetics Pharmaceuticals, maintaining a price target of $80.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 2:46 pm

T

Tigress Financial has maintained a Buy rating on AT&T and raised its price target from $29 to $30, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 2:45 pm